艾美拉唑钾盐
|
|
|
- CAS号:
- 161796-84-5
- 英文名:
- Esomeprazole potassium
- 英文别名:
- Esomeprazole potassium;(S)-Omeprazole potassium;Esomeprazole potassium USP/EP/BP;(S)-5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d];potassium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;(R)-5-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL)METHYLSULFINYL)BENZO[D]IMIDAZOL-1-IDE POTASSIUM SALT;6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt (1:1);1H-Benzimidazole,6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-,potassium salt (1:1)
- 中文名:
- 艾美拉唑钾盐
- 中文别名:
- 埃索拉唑钾盐;埃索美拉唑钾;艾美拉唑钾盐;埃索美拉唑钾盐;化合物 ESOMEPRAZOLE POTASSIUM SALT;6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钾盐;6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钾盐 (1:1)
- CBNumber:
- CB71229920
- 分子式:
- C17H20KN3O3S
- 分子量:
- 385.52
- MOL File:
- 161796-84-5.mol
|
|
|
艾美拉唑钾盐化学性质
-
蒸气压:
-
0Pa at 25℃
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
艾美拉唑钾盐性质、用途与生产工艺
艾美拉唑钾盐是一种质子泵抑制剂，艾美拉唑钾盐是奥美拉唑的S-异构体，通过特异性的质子泵抑制作用减少胃酸分泌，奥美拉唑的R-异构体和S-异构体具有相似的药效学特性。艾美拉唑钾盐为弱碱性药物，在壁细胞泌酸微管的高酸环境中浓集并转化为活性形式，从而抑制该部位的H+/K+-ATP酶(质子泵)，对基础胃酸分泌和受刺激后的胃酸分泌均产生抑制。
艾美拉唑钾盐盐是通过艾美拉唑钾盐成盐得到的，艾美拉唑钾盐盐能够降低对机体的刺激性，并且在机体中具有良好的溶解性，提高生物利用度，从而能够产生更理想的药理作用，常见的艾美拉唑钾盐盐主要有艾美拉唑钾盐钠盐、艾美拉唑钾盐钾盐、艾美拉唑钾盐镁盐。目前，艾美拉唑钾盐盐主要通过艾美拉唑钾盐成盐得到，因此，艾美拉唑钾盐的制备方法不仅影响艾美拉唑钾盐的纯度，而且影响艾美拉唑钾盐盐的纯度。
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。
Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.
Cell Viability Assay
|
Cell Line:
|
MDA-MB-468 cells
|
|
Concentration:
|
25 µM, 50 µM, 75 µM, 100 µM
|
|
Incubation Time:
|
20 hours
|
|
Result:
|
Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
|
Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.
|
Animal Model:
|
C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury
|
|
Dosage:
|
30 mg/kg, 300 mg/kg
|
|
Administration:
|
Oral gavage; daily; for 19 or 11 days
|
|
Result:
|
Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
|
艾美拉唑钾盐
上下游产品信息
上游原料
下游产品
161796-84-5, 艾美拉唑钾盐 相关搜索:
- 标准品
- 原料药
- 医用原料
- 医药原料药
- 化合物 ESOMEPRAZOLE POTASSIUM SALT
- 埃索美拉唑钾盐
- 艾美拉唑钾盐
- 6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钾盐 (1:1)
- 6-甲氧基-2-[(S)-[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑钾盐
- 埃索拉唑钾盐
- 埃索美拉唑钾
- 161796-84-5
- Esomeprazole potassium USP/EP/BP
- 1H-Benzimidazole,6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-,potassium salt (1:1)
- potassium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
- (S)-5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]
- (R)-5-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL)METHYLSULFINYL)BENZO[D]IMIDAZOL-1-IDE POTASSIUM SALT
- Esomeprazole potassium
- 6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt (1:1)
- (S)-Omeprazole potassium